V8 Peptides — Engineered Performance
Research Library
Wolverine Stack Research Design: BPC-157 + TB-500 Ratios
TB-500Stacks

Wolverine Stack Research Design: BPC-157 + TB-500 Ratios

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How should research be designed around the BPC-157 + TB-500 Wolverine Stack? The vial is 10 mg BPC-157 plus 10 mg TB-500, a 1:1 ratio by mass but about 1 : 1.6 by moles because TB-500 (about 889 g/mol) is smaller than BPC-157 (about 1419.5 g/mol). Each component concentration is 10 mg divided by diluent volume. Run vehicle, each peptide alone at its blend molar concentration, and the blend; analyze synergy against a stated additivity model. For laboratory research use only.

The Wolverine Stack is a co-lyophilized vial containing 10 mg of BPC-157 and 10 mg of TB-500, a fixed 1:1 mass ratio of two peptides with different molecular weights. That one fact generates most of the practical questions a laboratory faces: what ratio is that in moles, how do you tell the contribution of each peptide, what controls does a two-compound experiment need, and what can a pre-blended vial not do? This article is a design guide for combination experiments built on the blend. It is deliberately not a product comparison (see the stack comparison) or a reconstitution walkthrough (see blend reconstitution). The material is for laboratory research use only, and nothing here applies to people.

What is in the vial

The product page describes a single co-lyophilized vial with BPC-157 10 mg and TB-500 10 mg, 20 mg of peptide in total, purity specified at ≥98% by HPLC, supplied as lyophilized powder in a sealed clear glass vial and stored at 2–8 °C with −20 °C for long-term holding, protected from heat, moisture and light. The components are the fifteen-residue pentadecapeptide BPC-157 (about 1419.5 g/mol) and the N-acetylated heptapeptide TB-500, Ac-LKKTETQ, a fragment of thymosin beta-4 (about 889 g/mol). The page also notes that the pair come from different areas of the literature and that the proposed mechanisms do not overlap much, which is why the blend is used with each single peptide as a control arm.

Mass ratio is not molar ratio

Equal masses of two peptides of different size are not equal numbers of molecules. A receptor, enzyme or cytoskeletal target responds to molecules, so a combination experiment should be planned in moles.

QuantityBPC-157TB-500 fragmentFormula
Mass per vial10 mg10 mgLabeled
Molecular weightAbout 1419.5 g/molAbout 889.0 g/molFrom the sequences
Amount per vialAbout 7.05 µmolAbout 11.25 µmoln = m ÷ MW
Molar ratio (BPC-157 : TB-500)1 : 1.60n(TB-500) ÷ n(BPC-157)
Mass fraction50%50%m ÷ total

The consequence is that, at any dilution, the TB-500 fragment is present at about 1.6 times the molar concentration of BPC-157. A study that describes the blend as an "equal combination" should say equal by mass. If the design needs an equimolar combination, or any other ratio, a pre-blended 1:1 mass vial cannot provide it; separate vials of BPC-157 and TB-500 mixed at the planned ratio can. Net peptide content is below labeled mass for each component, and the correction may differ between them, which shifts the true ratio by an amount that quantification can resolve.

Stock and working-concentration arithmetic

The product page gives the relationship used for a blend: total concentration equals 20 mg divided by the diluent volume, and each component is half of that. Adding 1 mL gives 10 mg/mL of each component, 2 mL gives 5 mg/mL, 4 mL gives 2.5 mg/mL. The general forms are:

QuantityFormulaExample
Concentration of each componentc (mg/mL) = 10 mg ÷ V (mL)V = 2 mL gives 5 mg/mL of each
Total peptide concentrationc(total) = 20 mg ÷ VV = 2 mL gives 10 mg/mL total
Molar concentration, BPC-157c (mM) = 7.05 µmol ÷ V (mL)V = 2 mL gives about 3.5 mM
Molar concentration, TB-500c (mM) = 11.25 µmol ÷ V (mL)V = 2 mL gives about 5.6 mM
Working dilutionC1 × V1 = C2 × V2Dilute from stock just before use

Write both the mass and molar concentrations of each component on the label. The reconstitution calculator can be run once per component. As with any stock, the labeled mass is not the peptide content; for concentration-critical work, quantify the stock.

Control arms for a two-peptide experiment

The reason to use a blend is to ask whether the combination behaves differently from either component. That claim needs four arms at minimum: vehicle only, BPC-157 alone, TB-500 alone, and the combination. Each single-peptide arm should be at the same molar concentration it has in the combination arm, and the combination arm should be prepared the same way as the others, from the same lot and the same diluent. Without the single-peptide arms, an effect of the blend cannot be assigned to either component or to an interaction.

ArmContentsQuestion it answers
1Vehicle (diluent only)Baseline and vehicle effect
2BPC-157 alone at its molar concentration in the blendEffect of component 1
3TB-500 alone at its molar concentration in the blendEffect of component 2
4BlendCombined effect
5 (optional)Scrambled-sequence controls for each peptideSequence specificity
6 (optional)Single peptides at the molar concentration of the otherWhether the molar imbalance matters

To call an effect synergistic or additive, the analysis has to say what model of additivity was used (for example Bliss independence or Loewe additivity) and show the concentration-response curves for the single agents. A single concentration of the blend cannot distinguish additivity from synergy.

Where the two components come from in the literature

The components were studied in largely separate systems. BPC-157 work reported FAK-paxillin phosphorylation and migration in tendon fibroblasts (Chang et al., 2011) and VEGFR2-Akt-eNOS signaling in endothelial cells (Hsieh et al., 2017). The thymosin beta-4 literature centers on actin: the parent protein is a major G-actin-sequestering protein (Huff et al., 2001; Goldstein et al., 2012), and one study reported that it activated integrin-linked kinase and promoted cardiac cell migration, survival and repair (Bock-Marquette et al., 2004). The TB-500 fragment is the 17-23 region associated with actin binding, but whether the fragment reproduces the protein’s cellular activities is a question each laboratory should test, not assume from the parent.

Both families touch cell migration and endothelial biology, which is where a combination experiment is most likely to show an interaction, such as a transwell migration, scratch-wound or tube-formation assay. The mechanistic details for each are discussed in the BPC-157 overview, the TB-500 overview and BPC-157 vs TB-500.

What a co-lyophilized vial cannot do

A pre-blended vial removes a weighing step and fixes the ratio, which helps reproducibility. The same fixing is a limitation. The ratio cannot be varied, the components cannot be given at different times, and neither can be separated from the other. If the question concerns sequence of exposure, such as one peptide before the other, or if one component needs a solvent or pH that suits it better, separate vials are required. A blend is also only as stable as its less stable component, as the product page itself observes, so a reconstituted blend should be held cold, aliquoted for multi-day work and used within a window defined by the laboratory’s own stability data. See peptide blends and research stacks for the general reasoning.

Documentation for a blend

A blend places two demands on analysis: each peptide has to be resolved and accounted for. A chromatogram of the blend should show two main peaks, and an identity report should give the masses for both components (about 1419.5 Da and about 889 Da). The product page links the certificate for the listed lot, and the COA library lists published certificates; how to read a COA and BPC-157 and TB-500 third-party testing explain what to check.

RecordWhy
Lot number and COA referenceTies the blend to its analytical documentation
Molar and mass concentration of each componentPrevents ratio errors in later dilutions
Diluent, lot and volumeFixes the vehicle
Aliquot map and thaw logMakes freeze–thaw exposure visible
Control arms and their concentrationsAllows the combination claim to be assessed

The compounds are sold for laboratory research use only. Recording these items lets another laboratory reproduce the work or find where it differs.

Frequently asked questions

What is in the Wolverine Stack vial?

A single co-lyophilized vial with 10 mg of BPC-157 and 10 mg of TB-500, 20 mg of peptide in total, at a ≥98% HPLC purity specification.

Is the blend an equal molar ratio?

No. It is 1:1 by mass. Because TB-500 is the smaller molecule, the molar ratio of BPC-157 to TB-500 is about 1 to 1.6.

How do I calculate the concentration of each component?

Divide 10 mg by the diluent volume in mL to get mg/mL of each component. For molar values divide about 7.05 µmol (BPC-157) or about 11.25 µmol (TB-500) by the volume.

What controls does a combination experiment need?

Vehicle, BPC-157 alone, TB-500 alone and the blend, with single-peptide arms at the same molar concentration they have in the blend. Scrambled-sequence controls are optional additions.

Can I vary the ratio with a pre-blended vial?

No. The ratio is fixed at 1:1 by mass. Different ratios, or sequential exposure, need separate vials.

How do I show an effect is synergistic?

Run concentration-response curves for each single agent and the combination, and analyze them with a stated additivity model such as Bliss independence or Loewe additivity. One blend concentration cannot separate synergy from additivity.

Are the two peptides studied in the same systems?

Largely not. BPC-157 work reported FAK-paxillin and VEGFR2 signaling, while thymosin beta-4 work centers on actin sequestering and cell migration, so overlap is most likely in migration and endothelial assays.

Does the TB-500 fragment behave like thymosin beta-4?

The fragment is the 17-23 actin-binding region of a 43-residue protein. Whether it reproduces the protein’s activities in a given assay should be tested directly.

How should the reconstituted blend be stored?

Refrigerate it promptly, protect it from light, aliquot it for multi-day work and define its usable time with your own stability data. The product page says a blend is only as stable as its least stable component.

What should the blend’s certificate show?

Two resolved main peaks by HPLC, masses for both components (about 1419.5 Da and about 889 Da), the lot number and the test date.

Related reading: TB-500: Actin-Binding Motif and Cell Migration Assays, TB-500 and Thymosin β4 Wound Healing Animal Studies, How to Reconstitute TB-500: A Laboratory Guide.

References

  1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
  2. Hsieh MJ, Lee CH, Chueh HY, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
  3. Huff T, Müller CSG, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. doi:10.1016/S1357-2725(00)00087-X
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
  5. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
  6. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.